Case studies of subjects suffering from Alzheimer’s disease (heterozygous ApoEɛ4 carriers) reported by Stoykovich et al. [75] and Morrill et al. [76] demonstrated that treatment with KD for 10 months reduced (1) fasting glucose levels by 24–25%, (2) fasting insulin by 67–85.3%, (3) homeostatic model assessment for insulin resistance (HOMA-IR) by 75–88.8%, respectively. This evidence concerns the gene INS and Alzheimer disease.